BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1938129)

  • 1. Antinociceptive properties of inhibitors of endopeptidase 24.15.
    Kest B; Orlowski M; Molineaux CJ; Bodnar RJ
    Int J Neurosci; 1991; 56(1-4):141-9. PubMed ID: 1938129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endopeptidase 24.15 inhibition and opioid antinociception.
    Kest B; Orlowski M; Bodnar RJ
    Psychopharmacology (Berl); 1992; 106(3):408-16. PubMed ID: 1349191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increases in opioid-mediated swim antinociception following endopeptidase 24.15 inhibition.
    Kest B; Orlowski M; Bodnar RJ
    Physiol Behav; 1991 Oct; 50(4):843-5. PubMed ID: 1663630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that enzymatic conversion of N-[1(R,S)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-p-aminobenzoate, a specific inhibitor of endopeptidase 24.15, to N-[1(R,S)-carboxy-3-phenylpropyl]-Ala-Ala is necessary for inhibition of angiotensin converting enzyme.
    Cardozo C; Orlowski M
    Peptides; 1993; 14(6):1259-62. PubMed ID: 8134308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic inhibitors of endopeptidase EC 3.4.24.15: potency and stability in vitro and in vivo.
    Lew RA; Tomoda F; Evans RG; Lakat L; Boublik JH; Pipolo LA; Smith AI
    Br J Pharmacol; 1996 Jul; 118(5):1269-77. PubMed ID: 8818353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone.
    Lasdun A; Reznik S; Molineaux CJ; Orlowski M
    J Pharmacol Exp Ther; 1989 Nov; 251(2):439-47. PubMed ID: 2681686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a metalloendopeptidase-24.15. Inhibitor on renal hemodynamics and function in rats.
    Yang XP; Saitoh S; Scicli AG; Mascha E; Orlowski M; Carretero OA
    Hypertension; 1994 Jan; 23(1 Suppl):I235-9. PubMed ID: 8282366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of angiotensin converting enzyme by the metalloendopeptidase 3.4.24.15 inhibitor c-phenylpropyl-alanyl-alanyl-phenylalanyl-p-aminobenzoate.
    Chappell MC; Welches WR; Brosnihan KB; Ferrario CM
    Peptides; 1992; 13(5):943-6. PubMed ID: 1336190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endopeptidase-24.15 is the primary enzyme that degrades luteinizing hormone releasing hormone both in vitro and in vivo.
    Molineaux CJ; Lasdun A; Michaud C; Orlowski M
    J Neurochem; 1988 Aug; 51(2):624-33. PubMed ID: 3292705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of angiotensin converting enzyme in the vascular effects of an endopeptidase 24.15 inhibitor.
    Telford SE; Smith AI; Lew RA; Perich RB; Madden AC; Evans RG
    Br J Pharmacol; 1995 Mar; 114(6):1185-92. PubMed ID: 7620708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endopeptidase 24.15 modulates bradykinin-induced contraction in guinea-pig trachea.
    Da Silva A; Dhuy J; Waeldelé F; Bertrand C; Landry Y
    Eur J Pharmacol; 1992 Feb; 212(1):97-9. PubMed ID: 1372868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An inhibitor of endopeptidase-24.15 blocks the degradation of intraventricularly administered dynorphins.
    Molineaux CJ; Ayala JM
    J Neurochem; 1990 Aug; 55(2):611-8. PubMed ID: 1973455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of novel potent and stable inhibitors of endopeptidase EC 3.4.24.15.
    Shrimpton CN; Abbenante G; Lew RA; Smith I
    Biochem J; 2000 Jan; 345 Pt 2(Pt 2):351-6. PubMed ID: 10620512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endopeptidase 3.4.24.11 converts N-1-(R,S)carboxy-3-phenylpropyl-Ala-Ala-Phe-p-carboxyanilide into a potent inhibitor of angiotensin-converting enzyme.
    Williams CH; Yamamoto T; Walsh DM; Allsop D
    Biochem J; 1993 Sep; 294 ( Pt 3)(Pt 3):681-4. PubMed ID: 8379924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substrate-related potent inhibitors of brain metalloendopeptidase.
    Orlowski M; Michaud C; Molineaux CJ
    Biochemistry; 1988 Jan; 27(2):597-602. PubMed ID: 3162384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antinociception and paralysis induced by intrathecal dynorphin A.
    Herman BH; Goldstein A
    J Pharmacol Exp Ther; 1985 Jan; 232(1):27-32. PubMed ID: 2856940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel synthetic inhibitor of endopeptidase-24.15.
    Ukai Y; Li Q; Ito S; Mita S
    J Enzyme Inhib; 1996 Aug; 11(1):39-49. PubMed ID: 9204395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synaptosomal membrane-bound form of endopeptidase-24.15 generates Leu-enkephalin from dynorphin1-8, alpha- and beta-neoendorphin, and Met-enkephalin from Met-enkephalin-Arg6-Gly7-Leu8.
    Acker GR; Molineaux C; Orlowski M
    J Neurochem; 1987 Jan; 48(1):284-92. PubMed ID: 2878974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of endopeptidase-24.15 decreases blood pressure in normotensive rats.
    Genden EM; Molineaux CJ
    Hypertension; 1991 Sep; 18(3):360-5. PubMed ID: 1889849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antinociception and physical dependence produced by [D-Arg2] dermorphin tetrapeptide analogues and morphine in rats.
    Chaki K; Kawamura S; Kisara K; Sakurada S; Sakurada T; Sasaki Y; Sato T; Susuki K
    Br J Pharmacol; 1988 Sep; 95(1):15-22. PubMed ID: 2905901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.